Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Leases (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Current Leases for 10 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 1.42% year-over-year to $8.7 million, compared with a TTM value of $8.7 million through Sep 2025, up 1.42%, and an annual FY2024 reading of $8.5 million, up 1.57% over the prior year.
  • Current Leases was $8.7 million for Q3 2025 at Amicus Therapeutics, up from $8.6 million in the prior quarter.
  • Across five years, Current Leases topped out at $8.7 million in Q3 2025 and bottomed at $6.8 million in Q1 2021.
  • Average Current Leases over 5 years is $7.9 million, with a median of $8.0 million recorded in 2023.
  • The sharpest move saw Current Leases dropped 16.56% in 2021, then rose 15.43% in 2022.
  • Year by year, Current Leases stood at $7.4 million in 2021, then increased by 15.43% to $8.6 million in 2022, then decreased by 2.67% to $8.3 million in 2023, then increased by 1.57% to $8.5 million in 2024, then rose by 2.45% to $8.7 million in 2025.
  • Business Quant data shows Current Leases for FOLD at $8.7 million in Q3 2025, $8.6 million in Q2 2025, and $8.6 million in Q1 2025.